SubHero Banner
Text

Benlysta® (belimumab) – Expanded indication

July 27, 2022 - GSK announced the FDA approval of Benlysta (belimumab), for the treatment of patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.

Download PDF